The DEA Just Drew a Line Through Kratom. The Gas-Station Side Lost.

On July 1, the DEA filed notice that it’s putting 7-hydroxymitragynine — 7-OH for short — into Schedule I, the same legal category as heroin and LSD. Three chemical cousins go in with it. If you’ve walked past a gas-station counter and seen bright gummies or shot bottles promising an opioid-like lift without the opioid label, this is the stuff.

The DEA didn’t ban kratom. It banned the version of kratom built to feel like something else.

That distinction matters and it’s easy to miss in the headline. 7-OH occurs naturally in kratom leaf in tiny amounts — a compound your body barely notices at those doses. What’s sold at the counter is different: manufacturers extract and concentrate 7-OH until it behaves less like a mild plant alkaloid and more like a synthetic opioid, then press it into candy. The DEA’s threshold — 0.5% dry weight, or more than 1mg per unit — is drawn to catch exactly that manufactured version while leaving the whole, unprocessed leaf alone. DEA Administrator Terrance Cole called the products “highly concentrated” and “a growing threat to public safety,” and HHS Secretary Robert F. Kennedy Jr. backed the move the same day, saying the compounds “fuel addiction and put American lives at risk.”

The action didn’t come out of nowhere. The American Medical Association called for a 7-OH ban on June 9, pointing specifically at flavored gummy packaging marketed where teenagers shop, and citing a rise in poison-control calls involving kids. The DEA order runs for two years, extendable to three, while a permanent scheduling decision works through the normal process. The same order also temporarily schedules cychlorphine, an unrelated novel synthetic opioid.

Here’s the part worth sitting with if you’ve ever used kratom to get off something worse, or to avoid picking something worse back up: scheduling a chemical doesn’t relocate the person who was buying it. It relocates the market. Filter’s deputy editor Kastalia Medrano made this point the next day: 7-OH and cychlorphine “fit Schedule I criteria” because, in her framing, the criteria were written broadly enough that “all new drugs do” — the DEA isn’t being asked to prove a chemical is uniquely dangerous, just that it isn’t yet FDA-approved and has abuse potential. That’s not a defense of 7-OH gummies dosed for maximum shelf appeal. It’s a warning that a Schedule I order is a supply-side move, and supply-side moves have a documented habit of pushing people toward whatever replaces the banned thing on the shelf next month — often something nobody’s tested.

If you’ve been using 7-OH products and this order changes what’s available near you, that’s a real disruption worth planning around, not panicking over: naloxone still works on it, and it’s still worth having on hand. The compound didn’t get safer or more dangerous overnight. It just got harder to buy at the counter — which means the honest question isn’t whether the DEA made the right call on the chemistry. It’s what happens to the person who was relying on the gummy, three weeks from now, when the shelf is empty.